Heart Disease Trial, Recruiting NCT06863545 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06863545
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older.
  • People who have at least one artery with a significant plaque buildup, identified by a special heart scan called a CCTA, where the artery is either narrowed by 50% or more, or where plaque takes up 70% or more of the artery wall.
  • People whose plaque shows at least 2 of these specific features on the scan: low-density (soft) plaque, artery wall that has expanded outward around the plaque, a "napkin-ring" pattern in the plaque, or small scattered calcium deposits.
  • People whose affected artery segment is in one of three main heart arteries: the left anterior descending artery, the left circumflex artery, or the right coronary artery (in the upper or middle section of these arteries).
  • People who are able to confirm they understand the risks, benefits, and alternatives involved, and who can provide written consent before the study begins (or have an authorised representative do so on their behalf).

Who may not be able to join:

  • People whose target artery has already been treated to restore blood flow, or where such a procedure is already planned.
  • People currently experiencing an acute (sudden or severe) heart event, such as a heart attack or unstable chest pain.
  • People with severely reduced heart pumping function (specifically, a pumping capacity below 30%) or who have advanced heart failure symptoms classified as Class III or IV by standard medical guidelines.
  • People with uncontrolled or repeatedly occurring dangerous heart rhythm problems in the lower chambers of the heart.
  • People with a specific inherited cholesterol condition called homozygous familial hypercholesterolaemia.
  • People with active liver disease or significant liver problems.
  • People whose CCTA scan could not be successfully analysed for plaque.
  • People with a non-heart-related illness where life expectancy is less than 2 years.
  • People who are pregnant or breastfeeding.
  • People with a known allergy or medical reason they cannot take statins or a class of cholesterol-lowering medications called PCSK9 inhibitors.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xinyang Hu, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +86 0571 87784808

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 April 2025
Est. completion
1 April 2030

Where this trial is recruiting

🇨🇳 China 🇰🇷 South Korea

Primary endpoints

Major adverse cardiac and cerebrovascular events (MACCEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov